Non-HDL cholesterol should not generally replace LDL cholesterol in the management of hyperlipidaemia
Recently non-HDL cholesterol has been recommended to replace LDL cholesterol in the clinical management of dyslipidaemia routinely in general medical practice. The authors claim this is misguided.
Related stories
- Ketogenic Diet and Lipids
- Low Carbohydrate diets, Weight management, Type 2 diabetes and Dyslipidaemia
- Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis
- Diagnosis, management and prognosis of familial hypercholesterolaemia in a UK tertiary cardiac centre
- Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
- Does diet quality or nutrient quantity contribute more to health?
- Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options
- Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care
- Identifying FH Using a Blood Donor Screening Program With More Than 1 Million Volunteer Donors
- Higher circulating and tissue levels of Linoleic Acid associated with lower risk of major cardiovascular events
- Substituting red meat with high-quality plant protein sources results in favourable changes in blood lipids and lipoproteins
- Using metabolic profiling and gene expression analyses to explore molecular effects of replacing saturated fat with polyunsaturated fat—a randomized controlled dietary intervention study
- The Timing of Cardiovascular Health Decline and Its Association With Subclinical Atherosclerosis in Adulthood
- Is diet management helpful in familial hypercholesterolemia? Lynne Garton our Dietetic Adviser, explores.
- Statins may have a role in treating serious mental illness
- Increased intensity plus adherence maximises statin benefits
- Serum Cholesterol and Incident Alzheimer's Disease: Findings from the Adult Changes in Thought Study
- Higher intakes of fibre and wholegrains associated with lower rates of non-communicable diseases, including Cardiovascular Disease and Coronary Heart Disease.
- Risk of Ischemic Stroke and Total Cerebrovascular Disease in Familial Hypercholesterolemia May Not Be Higher
- CVD Prevention Return on Investment Tool
- Cholesterol Management Clinical Practice Guidelines in US
- REDUCE-IT: 25% Reduction in MACE With High-Dose EPA
- Raised Lp(a) Slashed in CV Patients on Novel Antisense Agent
- Integration of child–parent screening and cascade testing for familial hypercholesterolaemia
- Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk
- Walnut Consumption Controlled Trial
- Erectile Dysfunction Linked to Future CVD Events
- Ezetimibe - Likely to Be Beneficial For All
- Adverse effects of statin therapy: perception vs. the evidence
- Levels of lipoprotein(a) [Lp(a)] need to be reduced by substantially more than has been achieved in recent trials
- Impact of Healthy Lifestyle Factors on Life Expectancies in the US Population
- How much does plasma lipoprotein(a) need to be lowered to produce a clinically meaningful reduction in the risk of coronary heart disease?
- The effects of Vitamin D supplementation on statin adherence
- Effect of combined treatment with bisphosphonate and vitamin D on atherosclerosis in patients with systemic lupus erythematosus: a propensity score-based analysis
- Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels
- Diabetes UK Launches new evidence based guidelines for the prevention and management of diabetes
- Effects of walnut consumption on blood lipids and other cardiovascular risk factors: an updated meta-analysis and systematic review of controlled trials
- Portfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Meta-analysis of Controlled Trials
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
- The complex molecular genetics of familial hypercholesterolaemia
- Parents’ views of genetic testing and treatment of familial hypercholesterolemia in children: a qualitative study
- Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
- Marriage Tied to Lower Risk of Fatal Heart Attacks and Strokes
- How do the experiences and beliefs of adults and children with heterozygous familial hypercholesterolaemia influence their adherence to treatment? A systematic review of qualitative evidence protocol.
- Special Issue Section: Improving the Global Care of Familial Hypercholesterolaemia
- Familial hypercholesterolaemia patient support groups and advocacy: A multinational perspective
- Special Issue Section: Improving the Global Care of Familial Hypercholesterolaemia
- SHARP Annual Scientific Meeting 2018: Save the Date
- Issues & Answers in Cardiovascular Disease, 16-17 November 2018, EMCC Nottingham UK
- HEART UK responds to debate on the true benefits and risks of statins
- HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom
- HEART UK study finds high street restaurants serve meals with four times recommended saturated fat
- HEART UK responds to study that says good cholesterol may not always protect you from heart disease
Go to the main National Cholesterol Month page to find out even more!
Go